China Biopharma to Introduce an Immunotherapeutic Vaccine into China
China Biopharma, Inc., has reached a tentative agreement with Delmont Laboratory to introduce its immunotherapeutic vaccine Staphage Lysate that treats diseases of staphylococcal infection . According to this initial agreement, Delmont Laboratory will supply bulk materials and China Biopharma will ...Promising Therapy for Prostate Cancer
...-- An experimental drug therapy appears to have helped destroy allegedly inoperable prostate cancer in two patients in a clinical trial. Use of the immunotherapeutic agent MDX-010, or ipilimumab, in combination with standard hormone and radiation treatments helped eliminate the aggressive tumors, which had already ...Mayo researchers: Dramatic outcomes in prostate cancer study
...g therapy that was used in combination with standardized hormone treatment and radiation therapy. The men were participating in a clinical trial of an immunotherapeutic agent called MDX-010 or ipilimumab. In these two cases, physicians say the approach initiated the death of a majority of cancer cells and caused the t...ASCO Research Foundation Grant Will Support Study of Peregrine's Bavituximab in Lung Cancer
...d Steven W. King, president and CEO of Peregrine. "This clinical study should help us to better understand the biological effects of this new class of immunotherapeutic agents and generate data that will help guide the future clinical development and use of bavituximab." Dr. Gerber, assistant professor at the Har...Study to Investigate AHCC and the Swine Flu Virus
...SA. "The animal study published by my group in the recent issue of Journal of Nutrition suggested that dietary supplementation with AHCC may be immunotherapeutic for the West-Nile Virus potentially susceptible populations." said Tian Wang, Assistant Professor at the Departments of Microbiology, Immunology and ...Biotech company cofounded by BIDMC scientists targets natural killer T-cells
...[together with the company's third cofounder Brian Wilson, MD, PhD, of Massachusetts General Hospital] have extensive expertise in the applications of immunotherapeutic agents to human disease," explains Mark Chalek, Chief of Business Ventures at BIDMC. "Their research has helped to establish the important role of NKT...AlphaVax Announces Promising Results in Melanoma Studies
...ingle intervention we have seen in this model." "We are excited by the results obtained in the studies conducted by Dr. Wolchok's group at MSKCC. immunotherapeutic intervention with a novel vaccine vector such as ours may prove beneficial as a treatment strategy for patients with melanoma, and we hope to translat...CEL-SCI Corporation Releases Letter to Shareholders
...ne, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATOR...nger anti-tumor attack on multiple fronts. Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer...Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
...les and marketing of the company's Allovectin-7(R) immunotherapeutic product candidate in Turkey and the Turkish Republ...d a large Phase 2 trial evaluating Allovectin-7(R) immunotherapeutic as a single agent for patients with Stage III or I...h the FDA for a Phase 3 trial (the Allovectin-7(R) immunotherapeutic for Metastatic Melanoma, or AIMM trial) for certai...CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
...anted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck. Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the ...CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
...ne, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS...tronger anti-tumor attack on multiple fronts. Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer...Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
...y AnGes. Vical is conducting the Allovectin-7(R) immunotherapeutic for Metastatic Melanoma, or AIMM trial, a Phase 3 ...otal trial of the company's Allovectin-7(R) cancer immunotherapeutic as first-line therapy in chemotherapy-naive patien...d a large Phase 2 trial evaluating Allovectin-7(R) immunotherapeutic as a single agent for patients with Stage III or I...Another JDRF partner moves research forward with collaboration agreement for diabetes treatment
...on agreement with Genentech, Inc., a wholly owned member of the Roche Group, to further develop and potentially commercialize a novel antigen-specific immunotherapeutic designed to reverse the immune response that causes type 1 diabetes. To date, JDRF has awarded more than $29 million in research funding to 25 co...When acute hepatitis develops into chronic hepatitis
... The doctor thus has an opportunity to improve his diagnosis with so-called "marker genes" and to improve his treatment of the patients with targeted, immunotherapeutic measures", says Robert Geffers, who conducted the gene analysis of the blood tests. ...Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
...se I/II human clinical trial of BHT-3021, a DNA vaccine to reverse the immune response that causes type 1 diabetes. BHT-3021 is an antigen-specific immunotherapeutic DNA vaccine designed to reverse the underlying autoimmune disease process in diabetes, and slow down or halt further loss of pancreatic beta cell func...Mechanisms involved with tumor relapse identified
...interferon gamma as one of the signaling proteins involved with tumor relapse. The findings may help researchers develop tailored vaccines and other immunotherapeutic strategies to fight a number of cancers. Immunotherapy involves the manipulation of the immune system ?by introducing an antibody or lymphocytes, or i...Temple University Hospital investigates treatment for cervical dysplasia
...fected with HPV who have moderate to severe cervical dysplasia, a precancerous condition," explained Hernandez. Amolimogene is an investigational immunotherapeutic from MGI PHARMA, Inc. that is currently being evaluated in a pivotal phase 2 clinical program in multiple centers in the U.S., including Philadelphia....Innovative movies show real-time immune-cell activity within tumors
...ular requirements for T cell migration and T cell-tumor cell interactions. We should then be able to use results from this research to further improve immunotherapeutic strategies against cancer in patients." ...Faster immune system testing set to improve poultry quality
...atia had the basic idea twenty years ago but he had to wait for advances in molecular biology. "The test is ready but we need to develop the companion immunotherapeutic to convince an animal health company to take it on," explains project leader Dr William Ragland of Zagreb Biotek in Croatia. He had hoped that there w...Researchers discover new tumor defense system
...gy journal. Several forms of anti-cancer therapy rely on what is known as immunotherapeutic anti-cancer strategies, therapies that encourage the body's natural defenses, such as cytotoxic T lymphocytes, to aid in destroying tumors. However, immunotherapeutic methods are often not effective at removing established tumors for a number...Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use
...reliminary data critically important for improving immunotherapeutic delivery strategies in metastatic colorectal (CRC)...which is actively conducting clinical trials using immunotherapeutic dendritic cell (DC) vaccines to treat CRC, directe...unts for approximately 150,000 new cases annually. immunotherapeutic interventions using live-cell DC vaccines may pote...MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 4, 2009
...s diabetes pipeline includes AFRESA(R), an ultra rapid-acting insulin and MKC253, an inhaled formulation of human GLP-1. MannKind also has two cancer immunotherapeutic products in clinical development. MannKind maintains a website at http://www.mannkindcorp.com to which the company regularly posts copies of its pr...Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
...t transformation of colonic epithelial cells, and has profound expertise in immunotherapeutic targets CEA and EpCAM, which are being targeted by Micromet's product candi...s principal and co-investigator in numerous clinical trials exploring novel immunotherapeutic approaches. He has particular expertise in the role T cells play in cancer ...MannKind Submits NDA for AFRESA for Treatment of Diabetes
...s pipeline includes AFRESA(R), an ultra rapid-acting prandial insulin and MKC253, an inhaled formulation of human GLP-1. MannKind also has two cancer immunotherapeutic products in clinical development. MannKind maintains a website at http://www.mannkindcorp.com to which the company regularly posts copies of its pr...